Phone: 253-200-3166
Fax: 253-200-3167
What is Pluvicto?
Pluvicto (lutetium Lu 177 vipivotide tetraxetan) is a targeted radioligand therapy used for treating metastatic prostate cancer (mCRPC) that expresses prostate-specific membrane antigen (PSMA). Pluvicto is a promising treatment for advanced prostate cancer, offering improved survival and quality of life for eligible patients. It is specifically indicated for patients who have previously received chemotherapy.
How Pluvicto Works
Pluvicto combines a radioactive isotope (Lutetium-177) with a PSMA-targeting ligand. When administered, the ligand binds to PSMA-expressing cancer cells, delivering radiation directly to the tumor, helping to destroy cancer cells while minimizing damage to surrounding healthy tissues.
Administration
Intravenous infusion (IV) over about 30 minutes
Given once every six weeks for up to six doses
You may need imaging tests (PSMA PET scan) before treatment to confirm PSMA expression
Our healthcare team follows a comprehensive evaluation process to determine if Pluvicto is the appropriate treatment for you. This decision is based on several key factors, including your medical history, cancer progression, and overall health status.